Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?

References

• Bener A, Alsulaiman R, Doodson L, et al. Depression, hopelessness and social support among breast cancer patients: in highly endogamous population. Asian Pacific J Cancer Prev. 2017;18:1889.
   PubMedGoogle Scholar
• Globocan. Breast. (2018). http://gco.iarc.fr/today/data/factsheets/cancers/20-Breastfact-sheet.pdf
   Google Scholar
• Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Lyon: IARC Scientific Publication; 2007.
   Google Scholar
• Akram M, Iqbal M, Daniyal M, et al. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33. doi: 10.1186/s40659-017-0140-9
   PubMed Web of Science ®Google Scholar
• Sh R. The costs of breast cancer in the US [Internet]. 2015 [Updated 2015 Nov 16].
   Google Scholar
• Jakka S, Rossbach M. An economic perspective on personalized medicine. Hugo J. 2013;7(1):1–6. doi: 10.1186/1877-6566-7-1
   Google Scholar
• Shih Y-CT, Xu Y, Liu L, et al. Rising prices of targeted oral anticancer medications and associated financial burden on medicare beneficiaries. J Clin Oncol. 2017;35(22):2482. doi: 10.1200/JCO.2017.72.3742
   PubMed Web of Science ®Google Scholar
• Yousuf Zafar S. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst. 2016;108(5):djv370. doi: 10.1093/jnci/djv370
   PubMedGoogle Scholar
• Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? JNCI J Natl Cancer Inst. 2010;102(7):456–463. doi: 10.1093/jnci/djq029
   Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi: 10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer. 2008;8(3):224–233. doi: 10.3816/CBC.2008.n.025
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20(3):e175–e186. doi: 10.1016/S1470-2045(19)30026-9
   PubMed Web of Science ®Google Scholar
• Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360–1369. doi: 10.1016/S1470-2045(19)30420-6
   PubMed Web of Science ®Google Scholar
• Basile D, Gerratana L, Corvaja C, et al. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: a real-world study. Breast. 2021;57:104–112. doi: 10.1016/j.breast.2021.02.015
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Yamashiro H, Toh U, et al. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. Breast Cancer. 2021;28(1):145–160. doi: 10.1007/s12282-020-01138-4
   PubMed Web of Science ®Google Scholar
• Roché H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol. 2011;22(5):1000–1010. doi: 10.1093/annonc/mdq429
   PubMed Web of Science ®Google Scholar
• Nounou MI, ElAmrawy F, Ahmed N, et al. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer Basic Clin Res. 2015;9:BCBCR. S29420. doi: 10.4137/BCBCR.S29420
   PubMedGoogle Scholar
• Spring LM, Wander SA, Zangardi M, et al. CDK 4/6 inhibitors in breast cancer: Current controversies and future directions. Curr Oncol Rep. 2019;21(3):25. doi: 10.1007/s11912-019-0769-3
   PubMed Web of Science ®Google Scholar
• Çağlayan D, Koçak MZ, Geredeli Ç, et al. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer. Eur J Clin Pharmacol. 2023;79(2):243–248. doi: 10.1007/s00228-022-03435-7
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419
   PubMed Web of Science ®Google Scholar
• Harbeck N, Iyer S, Turner N, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27(6):1047–1054. doi: 10.1093/annonc/mdw139
   PubMed Web of Science ®Google Scholar
• Raphael J, Helou J, Pritchard KI, et al. Palbociclib in hormone receptor positive advanced breast cancer: a cost-utility analysis. Eur J Cancer. 2017;85:146–154. doi: 10.1016/j.ejca.2017.08.018
   PubMed Web of Science ®Google Scholar
• Galve-Calvo E, González-Haba E, Gostkorzewicz J, et al. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain. Clin Outcomes Res CEOR. 2018;10:773. doi: 10.2147/CEOR.S178934
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng X, Deng H, et al. Cost-effectiveness analysis of adding Palbociclib as a second-line endocrine therapy for HR+/HER2–metastatic breast cancer from the US and Chinese perspectives. Clin Ther. 2019;41(6):1175–1185. doi: 10.1016/j.clinthera.2019.04.033
   PubMed Web of Science ®Google Scholar
• Mistry R, May JR, Suri, G et al. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2-advanced or metastatic breast cancer: a US payer perspective. J Manag Care Spec Pharm. 2018;24(6):514–523. doi: 10.18553/jmcp.2018.24.6.514
   PubMed Web of Science ®Google Scholar
• Kay C, Martínez-Pérez C, Meehan J, et al. Current trends in the treatment of HR+/HER2+ breast cancer. Futur Oncol. 2021;17(13):1665–1681. doi: 10.2217/fon-2020-0504
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Chia SK, Simmons C, et al. Enhancing endocrine therapy combination strategies for the treatment of postmenopausal HR+/HER2– advanced breast cancer. Oncology. 2017;22(1):12–24. doi: 10.1634/theoncologist.2016-0185
   Google Scholar
• Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN guidelines insights: prostate cancer, version 1.2021: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2021;19(2):134–143. doi: 10.6004/jnccn.2021.0008
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas. Lancet Oncol. 2016;17(4):425–439. doi: 10.1016/S1470-2045(15)00613-0
   PubMed Web of Science ®Google Scholar
• Kornblum N, Zhao F, Manola J, et al. Randomized phase II trial of Fulvestrant plus Everolimus or placebo in postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. 2018;36(16):1556. doi: 10.1200/JCO.2017.76.9331
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. doi: 10.1200/JCO.2018.78.9909
   PubMed Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116–124. doi: 10.1001/jamaoncol.2019.4782
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936. doi: 10.1056/NEJMoa1810527
   PubMed Web of Science ®Google Scholar
• Li J, Huo X, Zhao F, et al. Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor–positive metastatic breast cancer. JAMA Netw Open. 2020;3(10):e2020312. doi: 10.1001/jamanetworkopen.2020.20312
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Erratum: updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (annals of oncology: official journal of the European Soc. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(11):1842. doi: 10.1093/annonc/mdz215
   PubMed Web of Science ®Google Scholar
• Sun J, Zhong X, Ma J, et al. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. Cancer Med. 2021;10(21):7665–7672. doi: 10.1002/cam4.4295
   PubMed Web of Science ®Google Scholar
• Loibl S, Turner NC, Ro J, et al. Palbociclib combined with Fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA‐3 results. Oncology. 2017;22(9):1028–1038. doi: 10.1634/theoncologist.2017-0072
   Google Scholar
• Ha MJ, Singareeka Raghavendra A, Kettner NM, et al. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: a large institutional study. Int J Cancer. 2022;150(12):2025–2037. doi: 10.1002/ijc.33959
   PubMed Web of Science ®Google Scholar
• Al-Ziftawi NH, Fasihul Alam M, Elazzazy SH, et al. Cost-effectiveness and cost-utility of Palbociclib versus Ribociclib in women with stage IV breast cancer: a real-world data evaluation. Int J Environ Res Public Health. 2023;20(1):512. doi: 10.3390/ijerph20010512
   Web of Science ®Google Scholar
• Mamiya H, Tahara RK, Tolaney SM, et al. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. Ann Oncol. 2017;28(8):1825–1831. doi: 10.1093/annonc/mdx201
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (Hr+)/human epidermal recep. J Oncol Pharm Pract. 2020;26(6):1486–1491. doi: 10.1177/1078155220934531
   PubMed Web of Science ®Google Scholar
• Schoninger SF, Blain SW. The ongoing search for biomarkers of CDK4/6 inhibitor responsiveness in breast cancer. Mol Cancer Ther. 2020;19(1):3–12. doi: 10.1158/1535-7163.MCT-19-0253
   PubMed Web of Science ®Google Scholar
• Asghar US, Kanani R, Roylance R, et al. Systematic review of molecular biomarkers predictive of resistance to CDK4/6 inhibition in metastatic breast cancer. JCO Precis Oncol. 2022;6:e2100002. doi: 10.1200/PO.21.00002
   PubMedGoogle Scholar
• Guarducci C, Bonechi M, Boccalini G, et al. Mechanisms of resistance to CDK4/6 inhibitors in breast cancer and potential biomarkers of response. Breast Care. 2017;12(5):304–308. doi: 10.1159/000484167
   PubMed Web of Science ®Google Scholar